I Was Told I Was TOO YOUNG For Breast Cancer!

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: mediastinum; lymph nodes between the lungs

As of November 2025, the patient was living with Stage IV metastatic breast cancer, described as lifelong and requiring ongoing treatment. She had also completed local treatment for a later breast lesion.

YouTube — The Patient StoryRead more →

Synchronous EGFR-mutated lung adenocarcinoma and metastatic breast cancer: surgery and adjuvant therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Two cancers: lung adenocarcinoma with EGFR exon 19 deletion; breast cancer ER-positive, PR-low, HER2 non-amplified.

Metastatic Site: lung

Follow-up CT on 26 December 2024 showed no recurrence, with disease-free survival estimated at 27 months to 1 April 2025 while on icotinib and letrozole maintenance.

PubMed CentralRead more →

Stage I AR-positive triple-negative invasive apocrine breast carcinoma: disease-free after surgery, radiotherapy and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: Triple-negative apocrine breast carcinoma with androgen receptor 90%

At 1-year follow-up, she remained disease-free with no clinical or radiologic evidence of recurrence.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Breast cancer history with severe MSSA infective endocarditis and vascular complications

Patient Info: Anonymized, Female

Her breast cancer treatment was historical; the active episode was MSSA infective endocarditis with embolic complications, treated successfully with antibiotics, hepatic artery embolization, and aortic valve replacement, followed by asymptomatic 3-month outpatient review.

PubMed CentralRead more →

HER2-positive DCIS with KLHL11 encephalitis and pulmonary adenocarcinoma in situ

Patient Info: Anonymized, Female, Under 40 | Stage 0

Biomarkers: Breast DCIS was ER/PR positive and HER2 positive

After local breast treatment and later lung resection, she was asymptomatic on levetiracetam and tamoxifen, with no recurrent fever, seizures, or ataxia reported.

PubMed CentralRead more →

Stage III Invasive Lobular Carcinoma: Stacy's Survivor Story

Patient Info: Stacy, Female | Stage III

Biomarkers: Hormone receptor-positive; HER2-negative

Stacy completed chemotherapy, mastectomy, radiation and reconstruction. She remained under regular monitoring and was taking Letrozole as part of a planned 10-year course.

Lobular Breast Cancer AllianceRead more →

Breast cancer care complicated by acute-on-chronic pulmonary embolism requiring emergency pulmonary thromboendarterectomy

Patient Info: Anonymized, Female, 40s

As of October 2025, the case focused on survival of an emergency pulmonary thromboendarterectomy during breast cancer care; breast cancer stage, subtype, treatment response, and recurrence status were not described.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient StoryRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

PT2N0M0 breast malignant adenomyoepithelioma: disease-free after excision and radiation

Patient Info: Anonymized, Female, 50s

Biomarkers: p63-positive; E-cadherin-positive; CK7-negative on pathology re-review; ER-negative; PR-negative; HER2/neu-negative; sentinel lymph node negative, triple negative

Alive with no evidence of disease after 78 months of follow-up following wide local excision and adjuvant breast radiation.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Stage I ER-positive PR-negative breast cancer: disease-free after lumpectomy, radiation and tamoxifen

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER 2+ in 60% of tumor cells; PR-negative; HER2/neu-negative; Ki-67 5%; 0/6 lymph nodes positive

At 15 months after surgery, she was disease-free, had no complaints, and was satisfied with the surgical result.

PubMed CentralRead more →

Breast Cancer: Josephine's Survivor Story

Patient Info: Josephine, Female, Under 40

As of October 2025, Josephine was cancer-free after melanoma in 2015 and breast cancer 2 years later, with breast cancer treatment including operations, chemotherapy, radiotherapy, and 5 years of anti-hormone therapy.

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

Stage I Invasive Lobular Carcinoma: Tammy's Survivor Story

Patient Info: Tammy, Female, 60s | Stage I

As of October 2025, Tammy had fully recovered and remained disease-free after Stage I invasive lobular breast cancer treated with partial mastectomy and a targeted week-long radiation course, with ongoing follow-up monitoring.

Cleveland ClinicRead more →

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage II Breast Cancer: Basma's Patient Story

Patient Info: Basma, Female, 40s | Stage II

As of October 2025, Basma had completed chemotherapy, tumor-removal surgery, and radiation with clear results and full recovery, while continuing daily oral medication and an injection every 3 months for prevention.